Save-the-Date

Mark your calendars for the 14th Drug Discovery for Neurodegeneration Workshop!

April 26-28, 2020

14th Drug Discovery for Neurodegeneration WORKSHOP

A Course on Translating Research into Novel Drug Targets

This interactive workshop is designed as an introductory course covering all aspects of drug discovery for neurodegenerative diseases, including Alzheimer’s, Parkinson’s, Huntington’s disease, Amyotrophic Lateral Sclerosis, Frontotemporal Degeneration, and Multiple Sclerosis.

Delegates are drawn from academia, industry, associations/societies, government and media.  The event attracts about 150-170 attendees allowing for a higher degree of interactivity and networking.

  • Academia 47% 47%
  • Industry 33% 33%
  • Non-profit 13% 13%
  • Government 3% 3%
  • Consulting 3% 3%
  • Other 1% 1%

%

Percentage of attendees selecting quality of the meeting as "Excellent" and "Very Good"

OBJECTIVES

  • Train a cadre of interdisciplinary scientists in the principles of drug discovery for neurodegenerative disease.
  • Provide a platform to exchange ideas, knowledge and resources about drug discovery for neurodegenerative disease.
  • Stimulate pre-clinical research in the discovery and testing of novel compounds aimed at the prevention and treatment of neurodegenerative disease.
  • Build public-private partnerships that will accelerate drug discovery for neurodegenerative disease.

BENEFITS FOR PARTICIPANTS

  • Gain an understanding of the drug discovery pipeline, from target identification to clinical trials
  • Learn from case studies and challenges associated with developing drugs for neurodegenerative diseases
  • Attend panel discussions to learn about careers outside academia
  • Attend panel discussions to learn about relevant grant opportunities and how to get funded
  • Partake in interactive breakout sessions
  • Join 1-1 mentoring sessions and networking events to engage with experts in the field
  • Present your poster

CONFIRMED SPEAKERS/PANELISTS/CHAIRS


Joseph Araujo—InterVivo Solutions
Dirk Beher, PhD—Asceneuron
Kurt Brunden, PhD—University of Pennsylvania
Charles Cywin, PhD—National Institute of Neurological Disorders and Stroke
Kuldip Dave, PhD—ALS Association
Philip De Jager, MD, PhD—Columbia University
Lauren Friedman, PhD—Alzheimer’s Drug Discovery Foundation
Jacques Galipeau, MD—University of Wisconsin, Madison
John Gerdes, PhD—Rio Pharma
Marcie Glicksman, PhD—Orign3n, Inc.
Edmund Graziani, PhD—Apertor Labs
Bill Holt, DO—PRA Health Sciences
Kirkland James, MD, PhD—Mayo Clinic
Walter Kostich, PhD—National Multiple Sclerosis Society
Zane Martin, PhD—National Institute on Aging
Douglas MacDonald, PhD—CHDI Foundation
Liliana Menalled, PhD—The Michael J. Fox Foundation
Elizabeth Mills, PhD—Alzheimer’s Drug Discovery Foundation
Kenneth Olivier, PhD—Biotech Primer
Meriel Owen, PhD—Alzheimer’s Drug Discovery Foundation
Natasha Penner, PhD—Biogen
Allen Reitz, PhD—ALS Biopharma
Edward Spack, PhD—MedaRed, Inc.
Nadine Tatton, PhD—The Association for Frontotemporal Degeneration
Leticia Toledo-Sherman, PhD—Rainwater Charitable Foundation
Alessio Travaglia, PhD—Alzheimer’s Drug Discovery Foundation
Iswariya (Ishu) Venkataraman, PhD—Euroimmun
D. Martin Watterson, PhD—Northwestern University
Maurice Zauderer, PhD—Vaccinex

SCIENTIFIC ADVISORY COMMITTEE

Kurt Brunden, PhD—University of Pennsylvania
Kuldip Dave, PhD—ALS Association
Howard Fillit, MD—ADDF
Lauren Friedman, PhD—ADDF
Marcie Glicksman, PhD—Orig3n
Walter Kostich, PhD—National MS Society
Frank Longo, MD, PhD—Stanford University
Suzana Petanceska, PhD—NIH/NIA
Edward Spack, PhD—MedaRed, Inc.
Alessio Travaglia, PhD—ADDF
D. Martin Watterson, PhD—Northwestern University